New hope for incurable germ cell tumors? drug trial targets stubborn cancers
NCT ID NCT04876456
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tests the drug cabozantinib in 50 adults with germ cell tumors (testicular, ovarian, or related cancers) that have not responded to standard chemotherapy. The goal is to see if the drug can shrink tumors or stop them from growing for at least 3 months. Participants will take cabozantinib until their disease gets worse, side effects become too severe, or they choose to stop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
Conditions
Explore the condition pages connected to this study.